Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

Blood

Volumn 121, Issue 12, 2013, Pages 2213-2223

  Jourdan, Eric ^a   Boissel, Nicolas ^b   Chevret, Sylvie ^b   Delabesse, Eric ^c   Renneville, Aline ^d   Cornillet, Pascale ^e   Blanchet, Odile ^f   Cayuela, Jean Michel ^b   Recher, Christian ^c   Raffoux, Emmanuel ^b   Delaunay, Jacques ^g   Pigneux, Arnaud ^h   Bulabois, Claude Eric ⁱ   Berthon, Céline ^j   Pautas, Cécile ^k   Vey, Norbert ^l   Lioure, Bruno ^m   Thomas, Xavier ⁿ   Luquet, Isabelle ^e   Terré, Christine ^o   Guardiola, Philippe ^f   Béné, Marie C ^p   Preudhomme, Claude ^d   Ifrah, Norbert ^f   Dombret, Hervé ^b   more..

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CANCER RESEARCH CENTER OF TOULOUSE   (France)

^d UNIV LILLE   (France)

^e REIMS UNIVERSITY HOSPITAL   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

^m UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁿ UNIVERSITÉ LYON 1   (France)

^o LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^p UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; LENOGRASTIM; METHOTREXATE; METHYLPREDNISOLONE; TRANSCRIPTION FACTOR RUNX1; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL OUTCOME; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE INTENSIFICATION; DRUG DOSE SEQUENCE; DRUG MEGADOSE; EVALUATION STUDY; EXON; FEMALE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; YOUNG ADULT; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; CONTROLLED CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR GENE;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CORE BINDING FACTORS; CYTARABINE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877930402     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-462879     Document Type: Article

References (32)

1. Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol. 2008;35(4):410-417.
2. Dombret H, Preudhomme C, Boissel N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol. 2009;16(2):92-97.
3. Dombret H. Gene mutation and AML pathogenesis. Blood. 2011;118(20):5366-5367.
4. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
5. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99(10):3517-3523.
6. Delaunay J, Vey N, Leblanc T, et al; French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques; Leucémies Aiguës Myéoblastiques de l’Enfant; Acute Leukemia French Association; Bordeaux-Grenoble-Marseille-Toulouse cooperative groups. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003; 102(2):462-469.
7. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004; 22(18):3741-3750.
8. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10(8):1288-1295.
9. Morschhauser F, Cayuela JM, Martini S, et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. J Clin Oncol. 2000;18(4): 788-794.
10. Schnittger S, Weisser M, Schoch C, et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003;102(8):2746-2755.
11. Perea G, Lasa A, Aventín A, et al; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. [t(8;21) and inv(16)] Leukemia. 2006;20(1):87-94.
12. Marková J, Marková J, Trnková Z, et al. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leuk Lymphoma. 2009;50(9):1448-1460.
13. Guièze R, Renneville A, Cayuela JM, et al. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience. Leukemia. 2010;24(7): 1386-1388.
14. Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol. 2010;28(23):3724-3729.
15. Liu Yin JA, O’Brien MA, Hills RK, et al. Minimal residual disease monitoring by RT-qPCR in core-binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14): 2826-2835.
16. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121(5):775-777.
17. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89(8):920-925.
18. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791-1799.
19. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-3468.
20. Boissel N, Leroy H, Brethon B, et al; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l’Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965-970.
21. Paschka P, Marcucci G, Ruppert AS, et al; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911.
22. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12): 2372-2379.
23. Lück SC, Russ AC, Du J, et al. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol. 2010; 148(6):925-937.
24. Park SH, Chi HS, Min SK, et al. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res. 2011;35(10): 1376-1383.
25. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593-5603.
26. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.
27. Kaplan EL, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
28. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A. 1972;135(2):185-206.
29. Cox DR. Regression models and life tables. J R Stat Soc Ser A. 1972;34(2):187-220.
30. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2012;119(15):3512-3522.
31. Lück SC, Russ AC, Botzenhardt U, et al. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia. 2011;25(11):1728-1738.
32. Kühn MW, Radtke I, Bullinger L, et al. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukaemia reveals new recurrent genomic alterations. Blood. 2012;119(10):e67-e75.